Agenus | AGEN - Current Assets


Agenus reported $133.44M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Agenus USD 133.44M 514K Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Celldex Therapeutics USD 534.66M 69.68M Dec/2025
CSL USD 11.85B 1000K Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Glaxosmithkline GBP 23.59B 390.44M Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
Intrexon USD 23.72M 45.04M Jun/2024
J&J USD 55.62B 1.01B Dec/2025
Jiangsu Hengrui CNY 51.49B 90.83M Dec/2025
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
MacroGenics USD 219.94M 12.15M Dec/2025
Merck EUR 13.23B 354M Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Northwest Biotherapeutics USD 7.2M 1.04M Sep/2025
Novartis USD 30.46B 2.26B Dec/2025
Novavax USD 978.28M 3.69M Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Veracyte USD 488.38M 39.15M Dec/2025